Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease.

Trial Profile

Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease.

Completed
Phase of Trial: Phase III/IV

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Hepatitis A vaccine inactivated; Hepatitis B vaccine recombinant
  • Indications Diphtheria; Haemophilus infections; Hepatitis A; Hepatitis B; Nosocomial pneumonia; Pneumococcal infections; Pneumonia; Tetanus
  • Focus Registrational; Therapeutic Use
  • Acronyms FinIP
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Jul 2017 Results assessing Direct and Indirect Effectiveness of the Ten-Valent Pneumococcal Conjugate Vaccine Against Carriage in three FinIP trials (FinIP, FinIPcarr and FinIP-carriage) published in the Pediatric Infectious Disease Journal
    • 20 Nov 2012 Status changed from active, no longer recruiting to completed.
    • 20 Nov 2012 Results published in the Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top